Sponsors / AXSM
AXSM

Axsome Therapeutics, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
21Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Addressing Dementia Via Agitation-Centered EvaluationNCT03226522AXSMPhase 2, Phase 3Completed2020-04-17Actual
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)NCT03881852AXSMPhase 2Completed2019-11-27Actual
Maximizing Outcomes in Treating Acute MigraineNCT03896009AXSMPhase 3Completed2019-12-10Actual
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)NCT04068051AXSMPhase 3Completed2020-09-22Actual
Initiating Early Control of Migraine Pain and Associated SymptomsNCT04163185AXSMPhase 3Completed2020-03-16Actual
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)NCT04634669AXSMPhase 2Terminated2022-02-18Actual
Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715AXSMPhase 3Completed2022-11-21Actual
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT04947553AXSMPhase 3Completed2024-12-03Actual
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNCT05059223AXSMPhase 3Completed2024-03-15Actual
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)NCT05113745AXSMPhase 3Completed2024-11-15Actual
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)NCT05550207AXSMPhase 3Completed2024-11-27Actual
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409AXSMPhase 3Completed2024-11-21Actual
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)NCT05972044AXSMPhase 3Completed2025-02-07Actual
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419AXSMPhase 3Completed2024-12-31Actual
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolNCT06413433AXSMPhase 3Recruiting2026-12Estimated
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)NCT06568367AXSMPhase 3Recruiting2026-12Estimated
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509AXSMPhase 3Terminated2025-02-17Actual
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating DisorderNCT06878976AXSMPhase 3Enrolling by invitation2027-12Estimated
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignNCT07398417AXSMPhase 3Recruiting2028-03Estimated
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolNCT07484217AXSMPhase 3Recruiting2028-12Estimated
Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaNCT07637162AXSMPhase 3Enrolling by invitation2028-05Estimated

Latest recorded trial changes